JP2005514333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514333A5 JP2005514333A5 JP2003534448A JP2003534448A JP2005514333A5 JP 2005514333 A5 JP2005514333 A5 JP 2005514333A5 JP 2003534448 A JP2003534448 A JP 2003534448A JP 2003534448 A JP2003534448 A JP 2003534448A JP 2005514333 A5 JP2005514333 A5 JP 2005514333A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- recombinant protein
- bacteriophage
- complex
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710132601 Capsid protein Proteins 0.000 claims description 14
- 101710125418 Major capsid protein Proteins 0.000 claims description 14
- 101710094648 Coat protein Proteins 0.000 claims description 13
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 13
- 101710141454 Nucleoprotein Proteins 0.000 claims description 13
- 101710083689 Probable capsid protein Proteins 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 241001515965 unidentified phage Species 0.000 claims description 6
- 241000709738 Enterobacteria phage fr Species 0.000 claims description 3
- 241001534160 Escherichia virus Qbeta Species 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 23
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 23
- 108010064733 Angiotensins Proteins 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 241001672158 Acinetobacter phage AP205 Species 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 102100028255 Renin Human genes 0.000 claims 2
- 108090000783 Renin Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000024335 physical disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000734 Angiotensin-1 Proteins 0.000 claims 1
- 102400000344 Angiotensin-1 Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 102000004881 Angiotensinogen Human genes 0.000 claims 1
- 108090001067 Angiotensinogen Proteins 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 241000709737 Enterobacteria phage GA Species 0.000 claims 1
- 241000191830 Enterobacteria phage L Species 0.000 claims 1
- 241001261579 Enterobacteria phage M11 Species 0.000 claims 1
- 241001278075 Enterobacteria phage MX1 Species 0.000 claims 1
- 241001278054 Enterobacteria phage NL95 Species 0.000 claims 1
- 241000709747 Enterobacteria phage R17 Species 0.000 claims 1
- 241000709743 Enterobacteria phage SP Species 0.000 claims 1
- 241000709739 Enterobacteria phage f2 Species 0.000 claims 1
- 241000709744 Enterobacterio phage MS2 Species 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000714209 Norwalk virus Species 0.000 claims 1
- 241001505332 Polyomavirus sp. Species 0.000 claims 1
- 241000709749 Pseudomonas phage PP7 Species 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 239000007771 core particle Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32699801P | 2001-10-05 | 2001-10-05 | |
| US33104501P | 2001-11-07 | 2001-11-07 | |
| US10/050,902 US7264810B2 (en) | 2001-01-19 | 2002-01-18 | Molecular antigen array |
| PCT/IB2002/000166 WO2002056905A2 (en) | 2001-01-19 | 2002-01-21 | Molecular antigen array |
| US39663702P | 2002-07-19 | 2002-07-19 | |
| PCT/EP2002/011219 WO2003031466A2 (en) | 2001-10-05 | 2002-10-07 | Angiotensin peptide-carrier conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010085112A Division JP2010189406A (ja) | 2001-10-05 | 2010-04-01 | アンジオテンシンペプチド−担体複合体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005514333A JP2005514333A (ja) | 2005-05-19 |
| JP2005514333A5 true JP2005514333A5 (cg-RX-API-DMAC10.html) | 2006-01-05 |
| JP4671389B2 JP4671389B2 (ja) | 2011-04-13 |
Family
ID=27517536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534448A Expired - Fee Related JP4671389B2 (ja) | 2001-10-05 | 2002-10-07 | アンジオテンシンペプチド−担体複合体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1432443B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4671389B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1558774B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2002362696B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2462857C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2321491T3 (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ531534A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003031466A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| RU2325202C2 (ru) * | 2002-07-19 | 2008-05-27 | Цитос Байотекнолоджи Аг | Конъюгаты грелин-носитель |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| CN101675993A (zh) | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| EP1706152A2 (en) * | 2004-01-20 | 2006-10-04 | Cytos Biotechnology AG | Particle-induced ghrelin immune response |
| NZ554387A (en) * | 2004-09-21 | 2009-09-25 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| EP1812051A2 (en) | 2004-10-05 | 2007-08-01 | Cytos Biotechnology AG | Vlp-antigen conjugates and their uses as vaccines |
| US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
| BRPI0616446A2 (pt) * | 2005-09-28 | 2011-06-21 | Cytos Biotechnology Ag | composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento |
| JP4970279B2 (ja) * | 2005-10-31 | 2012-07-04 | パナソニック株式会社 | セキュア処理装置、セキュア処理方法、難読化秘密情報埋め込み方法、プログラム、記憶媒体および集積回路 |
| AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| SI2032592T1 (sl) | 2006-06-12 | 2013-10-30 | Cytos Biotechnology Ag | Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov |
| JP2008007482A (ja) * | 2006-06-30 | 2008-01-17 | Univ Of Miyazaki | 昇圧作用を有する新規ポリペプチド |
| WO2009056651A1 (en) * | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
| JP2009137859A (ja) * | 2007-12-05 | 2009-06-25 | Univ Nihon | マウス多量体免疫グロブリンレセプターに反応するモノクローナル抗体 |
| KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Ｐｃｓｋ９ 백신 |
| KR102190180B1 (ko) | 2011-04-15 | 2020-12-11 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | Ｄｎａ 백신 |
| EP2794662A1 (en) | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| EP2891497B1 (en) | 2012-08-31 | 2020-07-01 | Osaka University | Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope |
| JP6001974B2 (ja) | 2012-09-21 | 2016-10-05 | アンジェスＭｇ株式会社 | アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン |
| WO2017071713A1 (en) | 2015-10-30 | 2017-05-04 | University Of Copenhagen | Virus like particle with efficient epitope display |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| AU2021252164B2 (en) | 2020-04-09 | 2026-07-02 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| TW202424182A (zh) | 2022-08-30 | 2024-06-16 | 瑞士商賽巴動物健康股份有限公司 | 經修飾的cmv類病毒粒子 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA934199B (en) * | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
| WO1998058952A1 (en) * | 1997-06-24 | 1998-12-30 | Proteus Molecular Design Limited | Angiotensin derivatives |
| WO2000023955A1 (en) * | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
| MXPA01005389A (es) * | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| EP1278542A2 (en) * | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
-
2002
- 2002-10-07 WO PCT/EP2002/011219 patent/WO2003031466A2/en not_active Ceased
- 2002-10-07 NZ NZ531534A patent/NZ531534A/en not_active IP Right Cessation
- 2002-10-07 CA CA2462857A patent/CA2462857C/en not_active Expired - Fee Related
- 2002-10-07 CN CN028189248A patent/CN1558774B/zh not_active Expired - Fee Related
- 2002-10-07 JP JP2003534448A patent/JP4671389B2/ja not_active Expired - Fee Related
- 2002-10-07 EP EP02800605A patent/EP1432443B1/en not_active Expired - Lifetime
- 2002-10-07 ES ES02800605T patent/ES2321491T3/es not_active Expired - Lifetime
- 2002-10-07 AU AU2002362696A patent/AU2002362696B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523189A5 (cg-RX-API-DMAC10.html) | ||
| US7666408B2 (en) | Angiotensin peptide-carrier conjugates and uses thereof | |
| RU2325202C2 (ru) | Конъюгаты грелин-носитель | |
| US7094409B2 (en) | Antigen arrays for treatment of allergic eosinophilic diseases | |
| JP4671389B2 (ja) | アンジオテンシンペプチド−担体複合体およびその使用 | |
| AU2002363382B2 (en) | Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases | |
| WO2008074895A1 (en) | Circular ccr5 peptide conjugates and uses thereof | |
| EP1750761A1 (en) | Medical uses of carrier conjugates of non-human tnf-peptides | |
| AU2002362696A1 (en) | Angiotensin peptide-carrier conjugates and uses thereof | |
| MX2010011373A (es) | Composiciones de vacuna para el tratamiento de la fiebre del dengue y uso de las mismas. | |
| CA2553594A1 (en) | Particle-induced ghrelin immune response | |
| US20110318300A1 (en) | User of Interleukin-1 Conjugates in the Treatment of Diabetes | |
| JP2010189406A (ja) | アンジオテンシンペプチド−担体複合体およびその使用 | |
| MX2007015781A (es) | Conjugados antigenos y sus usos. | |
| RU2004113655A (ru) | Конъюгаты ангиотензинового пептида с носителем и способы их применения | |
| WO2007039458A2 (en) | Hiv peptide conjugates and uses thereof | |
| JP2005512987A5 (cg-RX-API-DMAC10.html) | ||
| HK1067057B (en) | Angiotensin peptide-carrier conjugates and uses thereof | |
| ZA200402017B (en) | Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases. | |
| HK1068355B (en) | Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases |